IGSF3

Across TCGA pan-cancer cohorts, IGSF3 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated IGSF3 data layer compared with 21 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher IGSF3 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated IGSF3 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and HNSC show a favorable association.

CCRCC, PDAC, and HNSC are the cancer types where IGSF3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Tertile	All	1.000	0.872	.013	13	view →
PDAC	OS	Tertile	All	0.282	0.827	.020	8	view →
HNSC	DFS	Median	IV	0.836	0.570	.005	7	view →
LUAD	OS	Tertile	III,IV	0.865	0.563	.033	5	view →
LSCC	DFS	Median	All	0.806	0.615	.037	2	view →
GBM	DFS	Median	All	0.802	0.690	.031	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

IGSF3–CCRCC (OS)

Open the CCRCC breakdown →